



## Clinical trial results:

### A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PROGRESSED ON OR AFTER A TRASTUZUMAB-CONTAINING REGIMEN

#### Summary

EudraCT number	2019-001512-34
Trial protocol	ES BE IT
Global end of trial date	13 February 2024

#### Results information

Result version number	v3 (current)
This version publication date	28 February 2025
First version publication date	01 March 2022
Version creation reason	• New data added to full data set Final Analysis

#### Trial information

##### Trial identification

Sponsor protocol code	DS8201-A-U205
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04014075
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Daiichi Sankyo Inc.
Sponsor organisation address	211 Mt. Airy Rd., Basking Ridge, United States, 07920
Public contact	Global Clinical Director, Daiichi Sankyo Inc., +1 908-992-6400, CTRinfo_us@daiichisankyo.com
Scientific contact	Global Clinical Director, Daiichi Sankyo Inc., +1 908-992-6400, CTRinfo_us@daiichisankyo.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 April 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 February 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To investigate the efficacy of Trastuzumab Deruxtecan (DS-8201a) based on objective response rate (ORR) by independent central review based on Response Evaluation Criteria in Solid Tumors (RECIST), version (v)1.1

Protection of trial subjects:

The study protocol, amendments, the informed consent form(s) (ICF[s]), and information sheets were approved by the appropriate and applicable Independent Ethics Committees (IECs) or Institutional Review Boards (IRBs). The study was conducted in compliance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Council for Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and applicable regulatory requirement(s).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 November 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	European Union: 45
Country: Number of subjects enrolled	United States: 34
Worldwide total number of subjects	79
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	46

From 65 to 84 years	33
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 79 participants who met all inclusion criteria and no exclusion criteria were enrolled and treated at clinic centers in United States, Spain, Italy, United Kingdom, and Belgium.

### Pre-assignment

Screening details:

A total of 89 participants were screened and 10 participants failed screening.

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

This was an open-label study.

### Arms

Arm title	Trastuzumab Deruxtecan
-----------	------------------------

Arm description:

Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer received an intravenous (IV) infusion 6.4 mg/kg dose of trastuzumab deruxtecan every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.

Arm type	Experimental
Investigational medicinal product name	DS-8201a
Investigational medicinal product code	
Other name	Trastuzumab deruxtecan
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.

Number of subjects in period 1	Trastuzumab Deruxtecan
Started	79
Completed	0
Not completed	79
Physician decision	1
Adverse Event	15
Death	2
Miscellaneous	2
Progressive disease	53
Clinical Progression	4
Withdrawal by subject	2



## Baseline characteristics

### Reporting groups

Reporting group title	Overall
-----------------------	---------

Reporting group description: -

Reporting group values	Overall	Total	
Number of subjects	79	79	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	46	46	
From 65-84 years	33	33	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	58.8		
standard deviation	± 11.78	-	
Gender categorical			
Units: Subjects			
Female	22	22	
Male	57	57	

## End points

### End points reporting groups

Reporting group title	Trastuzumab Deruxtecan
Reporting group description: Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer received an intravenous (IV) infusion 6.4 mg/kg dose of trastuzumab deruxtecan every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.	

### Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma

End point title	Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma <sup>[1]</sup>
-----------------	--

#### End point description:

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported. Objective response rate was assessed in the Full Analysis Set at data cut-off dates (09 April 2021 and 08 Nov 2021).

End point type	Primary
----------------	---------

#### End point timeframe:

Up to 23 months

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.

End point values	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79			
Units: Percentage of Participants				
number (confidence interval 95%)				
Up to 16 months (data cut-off)	38.0 (27.3 to 49.6)			
Up to 23 months (data cut-off)	41.8 (30.8 to 53.4)			

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Progression-Free Survival (PFS) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma**

---

End point title	Progression-Free Survival (PFS) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
-----------------	---

End point description:

Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off dates (09 April 2021 and 08 Nov 2021).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 23 months

---

<b>End point values</b>	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79			
Units: months				
median (confidence interval 95%)				
Up to 16 months (data cut-off)	5.5 (4.2 to 7.3)			
Up to 23 months (data cut-off)	5.6 (4.2 to 8.3)			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Progression-Free Survival (PFS) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma**

---

End point title	Progression-Free Survival (PFS) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
-----------------	--

End point description:

Progression-free survival (PFS) by investigator assessment was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 09 April 2021.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 16 months (data cut-off)

---



<b>End point values</b>	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79			
Units: months				
median (confidence interval 95%)	5.5 (4.1 to 6.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma

End point title	Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
-----------------	--

End point description:

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on investigator assessment is reported. Objective response rate was assessed in the Full Analysis Set at data cut-off dates (09 April 2021 and 08 Nov 2021).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 23 months

<b>End point values</b>	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79			
Units: Percentage of Participants				
number (confidence interval 95%)				
Up to 16 months (data cut-off)	34.2 (23.9 to 45.7)			
Up to 23 months (data cut-off)	36.7 (26.1 to 48.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma

End point title	Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
End point description:	
Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. Overall survival (OS) was assessed in the Full Analysis Set at data cut-off dates (09 April 2021 and 08 Nov 2021).	
End point type	Secondary
End point timeframe:	
Up to 23 months	

<b>End point values</b>	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79 <sup>[2]</sup>			
Units: months				
median (confidence interval 95%)				
Up to 16 months (data cut-off)	99.9 (11.5 to 99.9)			
Up to 23 months (data cut-off)	12.1 (9.4 to 15.4)			

Notes:

[2] - For 16 months, 99.9=NA, median and upper limit CI not estimable due to insufficient number of events

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma

End point title	Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
End point description:	
Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR based on independent central review. Duration of Response (DOR) was assessed in the Full Analysis Set at data cut-off dates (09 April 2021 and 08 Nov 2021).	
End point type	Secondary
End point timeframe:	
Up to 23 months	

<b>End point values</b>	Trastuzumab Deruxtecan			
Subject group type	Reporting group			
Number of subjects analysed	79 <sup>[3]</sup>			
Units: months				
median (confidence interval 95%)				
Up to 16 months (data cut-off)	8.1 (4.1 to 99.9)			
Up to 23 months (data cut-off)	8.1 (5.9 to 99.9)			

Notes:

[3] - 99.9=NA, upper limit CI was not estimable. Curve for survivor function was above 0.5.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to final database lock of 24 Apr 2024.

Adverse event reporting additional description:

A Treatment-emergent adverse event (TEAE) is defined as an AE that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

### Reporting groups

Reporting group title	Trastuzumab Deruxtecan
-----------------------	------------------------

Reporting group description:

Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer received an intravenous (IV) infusion 6.4 mg/kg dose of trastuzumab deruxtecan every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.

Serious adverse events	Trastuzumab Deruxtecan		
Total subjects affected by serious adverse events			
subjects affected / exposed	33 / 79 (41.77%)		
number of deaths (all causes)	46		
number of deaths resulting from adverse events	11		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant Neoplasm Progression			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Lymphangiosis Carcinomatosa			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Tumour Haemorrhage			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural			

complications			
Animal Bite			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Exposure To Communicable Disease			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Basal Ganglia Infarction			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular Accident			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Generalised Tonic-Clonic Seizure			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Disease Progression			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Hyperpyrexia			

subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	3 / 79 (3.80%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dysphagia			

subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enteritis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal Obstruction			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Hepatobiliary disorders			
Bile Duct Stenosis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Interstitial Lung Disease			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		

Pneumonitis			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	1 / 1		
Pulmonary Embolism			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Obstruction			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Covid-19			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Pneumonia			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		
Bacterial Sepsis			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		



Covid-19 Pneumonia			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Device Related Infection			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Staphylococcal infection			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	2 / 79 (2.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Wound Infection			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Catheter site infection			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device Occlusion			
subjects affected / exposed	1 / 79 (1.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Trastuzumab Deruxtecan		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	79 / 79 (100.00%)		
Vascular disorders			
Hypotension			
subjects affected / exposed	6 / 79 (7.59%)		
occurrences (all)	6		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	33 / 79 (41.77%)		
occurrences (all)	60		
Asthenia			
subjects affected / exposed	12 / 79 (15.19%)		
occurrences (all)	17		
Pyrexia			
subjects affected / exposed	10 / 79 (12.66%)		
occurrences (all)	16		
Oedema Peripheral			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences (all)	4		
Mucosal inflammation			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences (all)	6		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	7 / 79 (8.86%)		
occurrences (all)	7		
Cough			
subjects affected / exposed	9 / 79 (11.39%)		
occurrences (all)	13		
Epistaxis			
subjects affected / exposed	8 / 79 (10.13%)		
occurrences (all)	8		
Interstitial Lung Disease			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences (all)	4		

Pneumonitis subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 5		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 5		
Depression subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4		
Investigations Weight Decreased subjects affected / exposed occurrences (all)	28 / 79 (35.44%) 31		
Platelet Count Decreased subjects affected / exposed occurrences (all)	14 / 79 (17.72%) 24		
Neutrophil Count Decreased subjects affected / exposed occurrences (all)	13 / 79 (16.46%) 18		
Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	13 / 79 (16.46%) 15		
White Blood Cell Count Decreased subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 12		
Alanine Aminotransferase Increased subjects affected / exposed occurrences (all)	8 / 79 (10.13%) 8		
Blood Alkaline Phosphatase Increased subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 11		
Blood Bilirubin Increased subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 7		
Weight increased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood creatinine increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 79 (6.33%)</p> <p>6</p> <p>4 / 79 (5.06%)</p> <p>4</p>		
<p>Nervous system disorders</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 79 (8.86%)</p> <p>9</p> <p>6 / 79 (7.59%)</p> <p>7</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Neutropenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thrombocytopenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>30 / 79 (37.97%)</p> <p>47</p> <p>8 / 79 (10.13%)</p> <p>17</p> <p>5 / 79 (6.33%)</p> <p>7</p>		
<p>Gastrointestinal disorders</p> <p>Nausea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal Pain</p>	<p>51 / 79 (64.56%)</p> <p>91</p> <p>35 / 79 (44.30%)</p> <p>58</p> <p>29 / 79 (36.71%)</p> <p>45</p> <p>23 / 79 (29.11%)</p> <p>36</p>		

subjects affected / exposed	11 / 79 (13.92%)		
occurrences (all)	14		
Gastrooesophageal Reflux Disease			
subjects affected / exposed	8 / 79 (10.13%)		
occurrences (all)	8		
Ascites			
subjects affected / exposed	5 / 79 (6.33%)		
occurrences (all)	7		
Dysphagia			
subjects affected / exposed	5 / 79 (6.33%)		
occurrences (all)	5		
Abdominal pain upper			
subjects affected / exposed	5 / 79 (6.33%)		
occurrences (all)	6		
Flatulence			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences (all)	4		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	19 / 79 (24.05%)		
occurrences (all)	19		
Renal and urinary disorders			
Urinary Retention			
subjects affected / exposed	5 / 79 (6.33%)		
occurrences (all)	6		
Acute Kidney Injury			
subjects affected / exposed	4 / 79 (5.06%)		
occurrences (all)	4		
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	7 / 79 (8.86%)		
occurrences (all)	7		
Infections and infestations			
Covid-19			
subjects affected / exposed	5 / 79 (6.33%)		
occurrences (all)	5		

Device related infection subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4		
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4		
Metabolism and nutrition disorders			
Decreased Appetite subjects affected / exposed occurrences (all)	26 / 79 (32.91%) 34		
Hypokalaemia subjects affected / exposed occurrences (all)	13 / 79 (16.46%) 16		
Hypoalbuminaemia subjects affected / exposed occurrences (all)	8 / 79 (10.13%) 10		
Hyponatraemia subjects affected / exposed occurrences (all)	6 / 79 (7.59%) 9		
Hypophosphataemia subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 September 2020	Updated endpoints to provide clarification, updated study schema, updated inclusion and exclusion criteria, updated guidelines for dose modifications, updated concomitant medications, treatments, and procedures, updated treatment period section, updated PK assessments due to COVID-19 infection, updated PK, biomarker, and AE analyses to provide clarification, added instructions related to COVID-19

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported